Scinus Group develops the Osilaris platform (formerly the Scinus Cell Expansion system) for scaling up stem cell cultivation using volume-expandable culture bags to enable 3D cultivation at clinical scale. The system is designed for Good Manufacturing Practice (GMP) compliance to help transition therapies from laboratory vials to clinical doses within a single platform. The company emphasizes clinical-scale, volume-expandable 3D growth rather than traditional 2D flask-based methods. Scinus plans to use the recent €3M strategic investment to expand operations and increase R&D efforts. Leadership changes tied to the investment include appointment of Dr. Erik Vossenaar as Executive Director and the addition of CEO Dr. Janeska de Jonge to the Board as a Non-Executive Director. The company was founded by Prof. Dr. Joost de Bruijn, Prof. Dr. Clemens van Blitterswijk, and FrankJan van der Velden.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2026